Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
303.06
+2.18 (0.72%)
At close: Nov 9, 2026, 4:00 PM EST
306.56
+3.50 (1.15%)
Pre-market: Nov 10, 2026, 7:34 AM EST
Krystal Biotech Revenue
Krystal Biotech had revenue of $127.34M in the quarter ending September 30, 2026, with 30.21% growth. This brings the company's total for the last twelve months to $470.03M, up 25.96% year-over-year. In the year 2025, Krystal Biotech had annual revenue of $389.13M with 33.94% growth. That makes Krystal Biotech the 11,639th largest company in the world by revenue and 2,326th in the United States.
Revenue (ttm)
$470.03M
Revenue Growth
+25.96%
P/S Ratio
19.11
Revenue / Employee
$1,593,305
Employees
295
Market Cap
8.98B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 389.13M | 98.62M | 33.94% |
| Dec 31, 2024 | 290.52M | 239.82M | 473.02% |
| Dec 31, 2023 | 50.70M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Madrigal Pharmaceuticals | 1.43B |
| Corcept Therapeutics | 963.65M |
| TG Therapeutics | 799.54M |
| Arrowhead Pharmaceuticals | 669.50M |
| Protagonist Therapeutics | 551.69M |
| Twist Bioscience | 431.80M |
| Rhythm Pharmaceuticals | 280.75M |
| ImmunityBio | 165.79M |
KRYS News
- 6 days ago - Krystal Biotech price target lowered to $380 from $403 at TD Cowen - TheFly
- 7 days ago - Krystal Biotech price target lowered to $375 from $400 at RBC Capital - TheFly
- 7 days ago - Krystal Biotech price target lowered to $412 from $416 at Citi - TheFly
- 7 days ago - Krystal Biotech falls -13.9% - TheFly
- 7 days ago - H.C. Wainwright positive on Krystal despite pipeline timing updates - TheFly
- 7 days ago - Krystal Biotech falls -11.7% - TheFly
- 7 days ago - Krystal pipeline catalysts experiencing delays, says RBC Capital - TheFly
- 7 days ago - Krystal Biotech Earnings Call Transcript: Q3 2026 - Transcripts